CO7151503A2 - Composiciones que comprenden benzodiazepinas de acción corta - Google Patents

Composiciones que comprenden benzodiazepinas de acción corta

Info

Publication number
CO7151503A2
CO7151503A2 CO14258220A CO14258220A CO7151503A2 CO 7151503 A2 CO7151503 A2 CO 7151503A2 CO 14258220 A CO14258220 A CO 14258220A CO 14258220 A CO14258220 A CO 14258220A CO 7151503 A2 CO7151503 A2 CO 7151503A2
Authority
CO
Colombia
Prior art keywords
compositions
short
acting benzodiazepines
benzodiazepines
acting
Prior art date
Application number
CO14258220A
Other languages
English (en)
Inventor
John Aitken Graham
Alan James Baillie
Kevin Richard Ward
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7151503(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of CO7151503A2 publication Critical patent/CO7151503A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona una composición con una benzodiazepina y al menos un excipientehigroscópico, en particular lactosa y/o dextrano.
CO14258220A 2012-05-22 2014-11-24 Composiciones que comprenden benzodiazepinas de acción corta CO7151503A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12168968 2012-05-22

Publications (1)

Publication Number Publication Date
CO7151503A2 true CO7151503A2 (es) 2014-12-29

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14258220A CO7151503A2 (es) 2012-05-22 2014-11-24 Composiciones que comprenden benzodiazepinas de acción corta

Country Status (42)

Country Link
US (2) US20150148338A1 (es)
EP (1) EP2852389B1 (es)
JP (1) JP6313286B2 (es)
KR (1) KR102116737B1 (es)
CN (2) CN104968348B (es)
AP (1) AP2014008084A0 (es)
AR (1) AR092008A1 (es)
AU (1) AU2013265295B2 (es)
BR (1) BR112014029108B1 (es)
CA (1) CA2874247C (es)
CL (1) CL2014003171A1 (es)
CO (1) CO7151503A2 (es)
DK (1) DK2852389T3 (es)
EA (1) EA032119B1 (es)
EC (1) ECSP14032553A (es)
ES (1) ES2651389T3 (es)
FR (1) FR21C1043I2 (es)
GE (1) GEP20186852B (es)
HK (1) HK1208164A1 (es)
HR (1) HRP20171872T1 (es)
HU (2) HUE037734T2 (es)
IL (1) IL235789B (es)
LT (2) LT2852389T (es)
LU (1) LUC00230I2 (es)
MA (1) MA37581B1 (es)
MX (1) MX368854B (es)
MY (1) MY185117A (es)
NL (1) NL301130I2 (es)
NO (2) NO2852389T3 (es)
NZ (1) NZ702063A (es)
PE (1) PE20150683A1 (es)
PH (1) PH12014502608B1 (es)
PL (1) PL2852389T4 (es)
PT (1) PT2852389T (es)
RS (1) RS56660B1 (es)
SG (1) SG11201407710VA (es)
SI (1) SI2852389T1 (es)
TN (1) TN2014000479A1 (es)
TW (1) TWI590826B (es)
UA (1) UA115063C2 (es)
WO (1) WO2013174883A1 (es)
ZA (1) ZA201408412B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193730B2 (en) 2006-07-10 2015-11-24 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (ja) * 2013-11-21 2015-05-28 小野薬品工業株式会社 全身麻酔および/または鎮静のための注射用組成物
ES2958606T3 (es) 2014-02-10 2024-02-12 Biolumic Ltd Mejoras en y relacionadas con el control de características de organismos fotosintéticos
PL3116296T3 (pl) 2014-03-14 2020-11-16 Biolumic Limited Sposób zwiększenia plonowania upraw i/lub odporności na stres
US9994578B2 (en) 2014-07-23 2018-06-12 Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd Benzodiazepine derivative and use thereof
US10750691B2 (en) 2014-09-17 2020-08-25 Biolumic Limited Methods of seed treatment and resulting products
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
CN109641000A (zh) 2016-04-14 2019-04-16 Paion英国有限公司 经口吸入和经鼻用的苯并二氮杂*类
CN108289897B (zh) * 2016-05-20 2020-07-28 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
CN109890198A (zh) 2016-08-22 2019-06-14 拜欧卢米克有限公司 种子处理系统、装置和方法
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
ES2803099B2 (es) * 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
TR199700587T1 (xx) 1995-01-06 1998-02-21 F. Hoffmann-La Roche Ag Hidroksimetil-imidazodiazepin ve bunlar�n esterleri.
WO1996023790A1 (de) 1995-02-02 1996-08-08 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepine
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
US9193730B2 (en) * 2006-07-10 2015-11-24 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
RS54645B1 (en) * 2009-11-05 2016-08-31 Glaxosmithkline Llc BENZODIAZEPINE AS A BROMODOMEN INHIBITOR
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Also Published As

Publication number Publication date
GEP20186852B (en) 2018-05-25
EP2852389A1 (en) 2015-04-01
PH12014502608A1 (en) 2015-01-21
LTPA2021521I1 (es) 2021-10-11
NL301130I1 (es) 2021-09-22
CN104968348A (zh) 2015-10-07
TW201400119A (zh) 2014-01-01
US20220040198A1 (en) 2022-02-10
CL2014003171A1 (es) 2015-06-19
RS56660B1 (sr) 2018-03-30
MY185117A (en) 2021-04-30
MA20150233A1 (fr) 2015-07-31
MX2014014225A (es) 2015-06-17
BR112014029108A2 (pt) 2017-06-27
TWI590826B (zh) 2017-07-11
CA2874247C (en) 2020-07-28
CA2874247A1 (en) 2013-11-28
NO2021041I1 (no) 2021-09-20
LT2852389T (lt) 2017-12-27
NL301130I2 (nl) 2021-10-25
HK1208164A1 (en) 2016-02-26
SI2852389T1 (en) 2018-02-28
MA37581B1 (fr) 2016-07-29
FR21C1043I1 (es) 2021-11-19
PH12014502608B1 (en) 2015-01-21
KR20150009601A (ko) 2015-01-26
HUE037734T2 (hu) 2018-09-28
AU2013265295B2 (en) 2017-08-31
HRP20171872T1 (hr) 2018-02-23
EA032119B1 (ru) 2019-04-30
NZ702063A (en) 2016-11-25
IL235789B (en) 2019-07-31
CN108578413A (zh) 2018-09-28
ECSP14032553A (es) 2018-11-30
TN2014000479A1 (en) 2016-03-30
LUC00230I2 (es) 2022-10-07
PE20150683A1 (es) 2015-06-03
US20150148338A1 (en) 2015-05-28
EA201492160A1 (ru) 2015-10-30
JP6313286B2 (ja) 2018-04-18
IL235789A0 (en) 2015-01-29
PL2852389T3 (pl) 2018-02-28
AU2013265295A1 (en) 2015-01-22
HUS2100040I1 (hu) 2021-10-28
ES2651389T3 (es) 2018-01-26
ZA201408412B (en) 2016-09-28
WO2013174883A1 (en) 2013-11-28
EP2852389B1 (en) 2017-10-18
UA115063C2 (uk) 2017-09-11
AR092008A1 (es) 2015-03-18
AP2014008084A0 (en) 2014-11-30
NO2852389T3 (es) 2018-03-17
CN104968348B (zh) 2018-04-17
BR112014029108B1 (pt) 2022-02-08
KR102116737B1 (ko) 2020-05-29
PT2852389T (pt) 2017-12-13
JP2015517552A (ja) 2015-06-22
SG11201407710VA (en) 2015-01-29
DK2852389T3 (en) 2017-12-18
MX368854B (es) 2019-10-18
FR21C1043I2 (fr) 2022-10-07
PL2852389T4 (pl) 2022-02-21

Similar Documents

Publication Publication Date Title
CO7151503A2 (es) Composiciones que comprenden benzodiazepinas de acción corta
RS53818B1 (en) PIROLOBENZODIAZEPINI I NJIHOVI conjugated
CR20150263A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
UY4235Q (es) Configuración aplicada en zapato
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
FI20115106A0 (fi) Ristikappale, jonka varsissa on avoin kanava
ITTO20100446A1 (it) Uso di un estratto vegetale ricco di polifenoli come agente antiossidante in associazione con un agente idratate oppure umettante.
GB201216243D0 (en) Determining common table definitions in distributed databases
PH12014502858A1 (en) Racecadotril lipid compositions
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
CL2015001564A1 (es) Composición que comprende una triazina y su uso en el tratamiento intramuscular de coccidiosis o enfermedad protozoaria relacionada, en un mamífero no humano.
CL2015001730A1 (es) Compuestos triciclos inhibidores del canal cftr; composicion y combinacion farmaceutica; y uso en el tratamiento de la enfermedad renal poliquistica y diarrea.
EP3057441A4 (en) Composition preventing necrotic enteritis in galloanserans
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
WO2014146111A3 (en) Analgesic compounds and methods of use
MX2014008390A (es) Formulaciones de romidepsina y sus usos.
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
BR112014000232A2 (pt) primeira composição, segunda composição e artigo
UY4198Q (es) Nuevo Diseño de una Plancha de Blisters en Forma de ?A?.
BR112013027391A2 (pt) formulação farmacêutica, frasco e kit
AR093813A1 (es) Composiciones en suspension de finafloxacina
UY4233Q (es) Configuración aplicada en zapato
BR112015020053B8 (pt) Composições para cuidado oral
CL2018001126A1 (es) Productos de construcción con grafeno u óxido de grafeno
BR112015014312A2 (pt) processo cosmético, uso cosmético, compostos c-xilosídeos e composições.